

# Tatsuya Yamashita

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4120750/publications.pdf>

Version: 2024-02-01

110  
papers

2,644  
citations

236612

25  
h-index

233125

45  
g-index

117  
all docs

117  
docs citations

117  
times ranked

3454  
citing authors

#	ARTICLE	IF	CITATIONS
1	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. <i>Liver Cancer</i> , 2014, 3, 458-468.	4.2	512
2	REFLECTâ€”a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. <i>Journal of Gastroenterology</i> , 2020, 55, 113-122.	2.3	123
3	Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 1674-1685.	3.6	104
4	Gut-derived <i>Enterococcus faecium</i> from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. <i>Genome Biology</i> , 2019, 20, 252.	3.8	78
5	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	4.2	71
6	Postâ€”progression survival and progressionâ€”free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. <i>Hepatology Research</i> , 2016, 46, 650-656.	1.8	66
7	Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 281-290.	0.9	64
8	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. , 2020, 8, e001367.		62
9	Association Between High-Avidity T-Cell Receptors, Induced by Î±-Fetoproteinâ€”Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2017, 152, 1395-1406.e10.	0.6	61
10	Liver Resection for Multiple Hepatocellular Carcinomas. <i>Annals of Surgery</i> , 2020, 272, 145-154.	2.1	61
11	Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 715-725.	2.0	58
12	Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 649-658.	3.7	58
13	Characteristics of Immune Response to Tumorâ€”Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 653-665.	3.6	56
14	Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. <i>Scientific Reports</i> , 2020, 10, 815.	1.6	41
15	Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Hepatology Research</i> , 2015, 45, 949-959.	1.8	40
16	Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy. <i>Hepatology Research</i> , 2018, 48, 956-966.	1.8	39
17	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	2.9	39
18	Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 369, 242-249.	3.2	37

#	ARTICLE	IF	CITATIONS
19	Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2020, 50, 871-884.	1.8	35
20	C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. <i>Metabolism: Clinical and Experimental</i> , 2021, 125, 154914.	1.5	33
21	Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0191026.	1.1	32
22	Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 364, 98-105.	3.2	31
23	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
24	Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. <i>Liver Cancer</i> , 2021, 10, 275-284.	4.2	29
25	Gadoxetic acid-enhanced magnetic resonance imaging reflects co-activation of $\beta$ -catenin and hepatocyte nuclear factor $\chi$ 4 in hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 205-216.	1.8	28
26	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. <i>Liver Cancer</i> , 2019, 8, 403-411.	4.2	28
27	Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. <i>PLoS ONE</i> , 2017, 12, e0188549.	1.1	27
28	Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version). <i>Hepatology Research</i> , 2019, 49, 981-989.	1.8	27
29	Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , 2019, 54, 549-557.	2.3	26
30	Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 70, 25-39.	3.6	26
31	Chronic liver disease enables gut <i>Enterococcus faecalis</i> colonization to promote liver carcinogenesis. <i>Nature Cancer</i> , 2021, 2, 1039-1054.	5.7	26
32	Severe Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Deceased-donor and Living-donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 3523-3535.	0.3	25
33	Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. <i>BMC Cancer</i> , 2017, 17, 870.	1.1	25
34	Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 2701-2711.	2.3	25
35	Beneficial Effect of Maintaining Hepatic Reserve during Chemotherapy on the Outcomes of Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 236-249.	4.2	24
36	Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. <i>Journal of Gastroenterology</i> , 2020, 55, 627-639.	2.3	23

#	ARTICLE	IF	CITATIONS
37	Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Cancer Science</i> , 2016, 107, 1263-1269.	1.7	22
38	Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Liver Cancer</i> , 2019, 8, 130-139.	4.2	21
39	Serum Laminin $\beta$ 2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 760-775.	3.6	21
40	Treatment strategies for hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2013, 43, 44-50.	1.8	19
41	Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1432-1440.	1.4	18
42	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1829-1835.	1.4	18
43	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2018, 53, 740-751.	2.3	17
44	Development of novel diagnostic system for pancreatic cancer, including early stages, measuring $\beta$ -microglobulin of whole blood cells. <i>Cancer Science</i> , 2019, 110, 1364-1388.	1.7	17
45	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. <i>Translational Oncology</i> , 2020, 13, 100777.	1.7	17
46	Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 966-973.	0.6	16
47	Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. <i>Journal of Gastroenterology</i> , 2020, 55, 701-711.	2.3	16
48	CX3CL1-CX3CR1 Signaling Deficiency Exacerbates Obesity-induced Inflammation and Insulin Resistance in Male Mice. <i>Endocrinology</i> , 2021, 162, .	1.4	16
49	Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. <i>BMC Gastroenterology</i> , 2019, 19, 217.	0.8	15
50	MicroRNA-10a Impairs Liver Metabolism in Hepatitis C Virus-Related Cirrhosis Through Derepression of the Circadian Clock Gene <i>Brain and Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1</i> . <i>Hepatology Communications</i> , 2019, 3, 1687-1703.	2.0	14
51	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 269-285.	2.3	14
52	BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2021, 15, 2203-2218.	2.1	14
53	BMP9-ID1 Signaling Activates HIF-1 $\alpha$ and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1475.	1.8	14
54	Immune responses against tumour-associated antigen-derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients. <i>Liver International</i> , 2018, 38, 2040-2050.	1.9	13

#	ARTICLE	IF	CITATIONS
55	Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170291.	1.1	13
56	Dickkopf-1 Promotes Angiogenesis and is a Biomarker for Hepatic Stem Cell-like Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2801.	1.8	13
57	Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 338.	1.1	12
58	Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacy. <i>Regenerative Therapy</i> , 2021, 18, 97-101.	1.4	12
59	A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2017, 37, 3397-3403.	0.5	12
60	Lidocaine spray alone is similar to spray plus viscous solution for pharyngeal observation during transoral endoscopy: a clinical randomized trial. <i>Endoscopy International Open</i> , 2017, 05, E47-E53.	0.9	11
61	Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. <i>Cancer Science</i> , 2019, 110, 903-912.	1.7	11
62	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <i>Cytotherapy</i> , 2021, 23, 137-145.	0.3	10
63	Current Status of Hepatocellular Carcinoma Treatment in Japan. <i>Clinical Drug Investigation</i> , 2012, 32, 15-23.	1.1	9
64	Immune responses of human T lymphocytes to novel hepatitis B virus-derived peptides. <i>PLoS ONE</i> , 2018, 13, e0198264.	1.1	9
65	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). <i>Medical Oncology</i> , 2019, 36, 52.	1.2	9
66	Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021, 51, 190-200.	1.8	9
67	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 320-320.	0.8	8
68	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8
69	Response to Importance of confounding factors in assessing fatty acid compositions in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 1773-1773.	1.9	7
70	Immune response to human telomerase reverse transcriptase-derived helper T cell epitopes in hepatocellular carcinoma patients. <i>Liver International</i> , 2018, 38, 1635-1645.	1.9	7
71	Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. <i>International Journal of Radiation Biology</i> , 2019, 95, 571-579.	1.0	7
72	Tumor lysis syndrome in a patient with metastatic melanoma treated with nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 935-939.	0.4	7

#	ARTICLE	IF	CITATIONS
73	Study Protocol for Pleiotropic Effects and Safety of Sodium <sup>+</sup> Glucose Cotransporter <sup>2</sup> Inhibitor Versus Sulfonylurea in Patients with Type <sup>2</sup> Diabetes and Nonalcoholic Fatty Liver Disease. <i>Diabetes Therapy</i> , 2020, 11, 549-560.	1.2	7
74	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. <i>PLoS ONE</i> , 2020, 15, e0232089.	1.1	7
75	The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. <i>Hepatology International</i> , 2021, 15, 695-706.	1.9	7
76	A novel $\alpha$ -fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 4021.	1.6	6
77	Restorative effect of adipose tissue-derived stem cells on impaired hepatocytes through Notch signaling in non-alcoholic steatohepatitis mice. <i>Stem Cell Research</i> , 2021, 54, 102425.	0.3	6
78	Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical Trial. <i>JMIR Research Protocols</i> , 2020, 9, e17904.	0.5	6
79	Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver. <i>Liver Cancer</i> , 2020, 9, 261-274.	4.2	5
80	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated $\alpha$ -fetoprotein: Outcomes by treatment <sup>±</sup> emergent ascites. <i>Hepatology Research</i> , 2021, 51, 715-721.	1.8	5
81	Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. <i>Hepatology Research</i> , 2021, 51, 890-901.	1.8	5
82	Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup.. <i>Journal of Clinical Oncology</i> , 2020, 38, 526-526.	0.8	5
83	Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 63-70.	0.4	4
84	Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. <i>American Journal of Cancer Research</i> , 2021, 11, 3163-3175.	1.4	4
85	Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. <i>Life</i> , 2020, 10, 177.	1.1	3
86	Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 323-323.	0.8	3
87	The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2022, 12, 987.	1.6	3
88	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. <i>Cancer Medicine</i> , 2020, 9, 4907-4917.	1.3	2
89	IL <sup>28B</sup> variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1813-1820.	1.4	2
90	REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4162-TPS4162.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Dynamical changes of treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice.. <i>Journal of Clinical Oncology</i> , 2019, 37, 407-407.	0.8	2
92	Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repair. <i>Regenerative Therapy</i> , 2021, 18, 497-507.	1.4	2
93	Distinct notch signaling expression patterns between nucleoside and nucleotide analogues treatment for hepatitis B virus infection. <i>Biochemical and Biophysical Research Communications</i> , 2018, 501, 682-687.	1.0	1
94	Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4607.	1.3	1
95	Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. <i>Scientific Reports</i> , 2021, 11, 12885.	1.6	1
96	Treatment patterns and medical costs after hepatectomy in real-world practice for patients with hepatocellular carcinoma in Japan. <i>Hepatology Research</i> , 2021, 51, 1073-1081.	1.8	1
97	Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4644-4644.	0.8	1
98	Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 355-355.	0.8	1
99	Comparative analysis of medical costs after hepatectomy versus radiofrequency ablation in patients with hepatocellular carcinoma in real-world clinical practice. <i>Hepatology Research</i> , 2022, , .	1.8	1
100	Oral Corticosteroids Impair Mucin Production and Alter the Posttransplantation Microbiota in the Gut. <i>Digestion</i> , 2022, 103, 269-286.	1.2	1
101	A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4095-4095.	0.8	1
102	Argon plasma coagulation therapy after submucosal injection of normal saline solution for local recurrence of large nonampullary duodenal neoplasm. <i>VideoGIE</i> , 2016, 1, 55-56.	0.3	0
103	Treatment Outcome and Prognosis of Portal Vein Thrombosis. <i>Gastroenterology</i> , 2017, 152, S1146.	0.6	0
104	Current positioning of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. <i>Annals of Oncology</i> , 2018, 29, vii10.	0.6	0
105	A case of traumatic diaphragmatic hernia that caused obstruction of middle hepatic vein. <i>Acta Hepatologica Japonica</i> , 2021, 62, 413-419.	0.0	0
106	Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 403-403.	0.8	0
107	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
108	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0

#	ARTICLE	IF	CITATIONS
109	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0
110	Management of biliary stricture in patients with IgG4-related sclerosing cholangitis. , 2020, 15, e0232089.		0